Aberrant gene promoter methylation in plasma cell dyscrasias

Experimental and Molecular Pathology

Volumn 84, Issue 3, 2008, Pages 256-261

  Martin, Paloma ^a   Garcia Cosio, Monica ^b   Santon, Almudena ^b   Bellas, Carmen ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Methylation; Monoclonal gammopathy of undetermined significance; Myeloma; Plasmacytoma

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA REPAIR; FEMALE; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MONOCLONAL IMMUNOGLOBULINEMIA; PLASMA CELL DYSCRASIA; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS; PLASMACYTOMA; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEINS;

EID: 45849122775     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2008.02.003     Document Type: Article

References (51)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson Jr. J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., and Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
2. Chim C.S., Kwong Y.L., Fung T.K., and Liang R. Methylation profiling in multiple myeloma. Leuk.Res. 28 (2004) 379-385
3. Chim C.S., Fung T.K., Wong K.F., Lau J.S., and Liang R. Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J. Hum. Genet. 51 (2006) 832-838
4. Chim C.S., Lyang R., Leung M.H., and Kwong Y.L. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J. Clin. Pathol. 60 (2007) 104-106
5. Choy K.W., Pang C.P., To K.F., Yu C.B., Ng J.S., and Lam D.S. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1344-1349
6. Cohen O., Inbal B., Kissil J.L., Raveh T., Berissi H., Spivak-Kroizaman T., Feinstein E., and Kimchi A. DAP-kinase participates in TNF-alfa and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol. 146 (1999) 141-148
7. Das P.M., and Singal R. DNA methylation and cancer. J. Clin. Oncol. 22 (2004) 4632-4642
8. Dominguez G., Silva J., Garcia J.M., Silva J.M., Rodríguez R., Muñoz C., Chacon I., Sanchez R., Carballido J., Colas A., España P., and Bonilla F. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat. Res. 530 (2003) 9-17
9. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61 (2001) 3225-3229
10. 6-methylguanine-DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94 (2002) 26-32
11. Fink D., Nebel S., Norris P.S., Aebi S., Lin T.P., Nehme A., Christen R.D., Haas M., McLeod C.L., and Howel S.B. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br. J. Cancer 77 (1998) 703-708
12. Galm O., Wilop S., Reichelt J., Jost E., Gehbauer G., Herman J.G., and Osieka R. DNA methylation changes in multiple myeloma. Leukemia 18 (2004) 1687-1692
13. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev., Cancer 4 (2004) 296-307
14. Gonzalez M., Mateos M.V., Garcia-Sanz R., Balanzategui A., Lopez-Perez R., Chillon M.C., Gonzalez D., Alaejos I., and San Miguel J.F. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia 14 (2000) 183-187
15. Gonzalez-Paz N., Chng W.J., McClure M.F., Blood E., Oken M.M., Van Ness B., James C.D., Kurtin P.J., Henderson K., Ahmann G.J., Gertz M., Lacy M., Dispenzieri A., Greipp P.R., and Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109 (2007) 1228-1232
16. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Blade J., Boccadoro M., Child J.A., Avet-Loiseau H., Kyle R.A., Lahuerta J.J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., and Westin J. International staging system for multiple myeloma. J. Clin. Oncol. 23 (2005) 3412-3420
17. INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 98 (2001) 244-246
18. Hau P., Stupp R., and Hegi M.E. MGMT methylation status: the advent of stratified therapy in glioblastoma?. Dis. Markers 23 (2007) 97-104
19. Hayslip J., and Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol. Cancer 5 (2006) 44
20. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9821-9826
21. Hiraga J., Kinoshita T., Ohno T., Mori N., Ohashi H., Fukami S., Noda A., Ichikawa A., and Naoe T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int. J. Hematol. 84 (2006) 248-255
22. Jiricny J., and Nystrom-Lahti M. Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. 10 (2000) 157-161
23. Jones P.A., and Baylin S.B. The fundamental role of epigenetics events in cancer. Nat. Rev., Genet. 3 (2002) 415-428
24. Katzenellenbogen R.A., Baylin S.B., and Herman J.G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93 (1999) 4347-4353
25. Kitajima Y., Miyazaki K., Matsukura S., Tanaka M., and Sekiguchi M. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Gastric Cancer 6 (2003) 86-95
26. Kotoula V., Hytiroglou P., Kaloutsi V., Barbani S., Kouidou S., and Papadimitriou C.S. Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin. Leuk. Lymphoma 43 (2002) 393-399
27. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 351 (2004) 1860-1873
28. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance. Br. J. Haematol. 134 (2006) 573-589
29. Le M.H., and Yang H.Y. Regulators of G1 cyclin-dependent kinases and cancer. Cancer Metastasis Rev. 22 (2003) 435-449
30. Liu K., Zuo C., Luo Q.K., Suen J.Y., Hanna E., and Fan C.Y. Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn. Mol. Pathol. 12 (2003) 50-56
31. Martin P., Santon A., Garcia-Cosio M., and Bellas C. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod. Path. 19 (2006) 914-921
32. Mateos M.V., Garcia-Sanz R., Lopez-Perez R., Moro M.J., Ocio E., Hernandez J., Megido M., Caballero M.D., Fernandez-Calvo J., Barez A., Almeida J., Orfao A., Gonzalez M., and San Miguel J.F. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br. J. Haematol. 118 (2002) 1034-1040
33. Murata H., Khattar N.H., Gu L., and Li G.M. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 223 (2005) 143-150
34. Nagy E., Beck Z., Kiss A., Csoma E., Telek B., Konya J., Olah E., Rak K., and Coth F.P. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur. J. Cancer 39 (2003) 2298
35. Ng M.H. Death associated protein kinase: from regulation of apoptosis to tumour suppressive functions and B-cell malignancies. Apoptosis 7 (2002) 261-270
36. Ng M.H., Chung Y.F., Lo K.W., Wickman N.W., Lee J.C., and Huang D.P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89 (1997) 2500-2506
37. Ng M.H., To K.W., Lo K.W., Chan S., Tsang K.S., Cheng S.H., and Ng H.K. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin. Cancer Res. 7 (2001) 1724-1729
38. Paz M.F., Yaya-Tur R., Rojas-Marcos I., Reynes G., Pollan M., Aguirre-Cruz L., Garcia-Lopez J.L., Piquer J., Safont M.J., Balana C., Sanchez-Cespedes M., Garcia-Villanueva M., Arribas L., and Esteller M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 10 (2004) 4933-4938
39. Quelle D.E., Zindy F., Ashmun R.A., and Sherr C.J. Alternative ready frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducting cell cycle arrest. Cell 83 (1995) 993-1000
40. 6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br. J. Haematol. 123 (2003) 475-478
41. Sakumi K., Shiraishi A., Shimizu S., Tsuzuki T., Ishikawa T., and Sekiguchi M. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res. 57 (1997) 2415-2418
42. INK4b gene expression with proliferative activity and the clinical course of multiple myeloma. Haematologica 91 (2006) 1551-1554
43. Seidl S., Ackermann J., Kaufmann H., Keck A., Nösslinger T., Zielinski C.C., Drach J., and Zöchbauer-Müller S. DNA-methylation analysis identifies the E-cadherin gene as a potential maker of disease progression in patients with monoclonal gammopathies. Cancer 100 (2004) 2598-2606
44. Takahashi T., Shivapurkar N., Reddy J., Suzuki M., Miyajima K., Zhou X., Bekele B.N., Gazdar A.F., and Wistuba I.I. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin. Cancer Res. 10 (2004) 2928-2935
45. Tang X., Khuri F.R., Lee J.J., Kemp B.L., Liu D., Hong W.K., and Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I nonsmall-cell lung cancer. J. Natl. Cancer Inst. 92 (2000) 1511-1516
46. INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 15 (2001) 157-165
47. Velangi M.R., Matheson E.C., Morgan G.J., Jackson G.H., Taylor P.R., Hall A.G., and Irving J.A. DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis 25 (2004) 1795-1803
48. Voso M.T., Gumiero D., D'Alo' F., Guida F., Mansuelo G., Di Febo A.L., Massini G., Martín M., Larocca L.M., Hohaus S., and Leone G. DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica 91 (2006) 1252-1256
49. Wijdenes J., Vooijs W.C., Clement C., Post J., Morard F., Vita N., Laurent P., Sun R.X., Klein B., and Dore J.M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol. 94 (1996) 318-323
50. Yu J., Zhang H., Gu J., Lin S., Li J., Lu W., Wang Y., and Zhu J. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4 (2004) 65
51. ARF locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 21 (2000) 2057-2064